1. Eckert T, Barnes A, Dhawan V, Frucht S, Gordon MF, Feigin AS, et al. FDG PET in the differential diagnosis of parkinsonian disorders. Neuroimage. 2005;26(3):912-21.
2. Eidelberg D, Moeller JR, Dhawan V, Spetsieris P, Takikawa S, Ishikawa T, et al. The metabolic topography of parkinsonism. J Cereb Blood Flow and Metab. 1994;14(5):783-801.
3. Hosey LA, Thompson JL, Metman LV, van den Munckhof P, Braun AR. Temporal dynamics of cortical and subcortical responses to apomorphine in Parkinson disease: an H2(15)O PET study. Clin Neuropharmacol. 2005;28(1):18-27.
4. Huang C, Tang C, Feigin A, Lesser M, Ma Y, Pourfar M, et al. Changes in network activity with the progression of Parkinson’s disease. Brain. 2007;130(Pt 7):1834-46.
5. Kawachi T, Ishii K, Sakamoto S, Sasaki M, Mori T, Yamashita F, et al. Comparison of the diagnostic performance of FDG-PET and VBM-MRI in very mild Alzheimer’s disease. Eur J Nucl Med Mol Imaging. 2006;33(7):801-9.
6. Hosokai Y, Nishio Y, Hirayama K, Takeda A, Ishioka T, Sawada Y, et al. Distinct patterns of regional cerebral glucose metabolism in Parkinson’s disease with and without mild cognitive impairment. Mov Disord. 2009;24(6):854-62.
7. Soonawala D, Amin T, Ebmeier KP, Steele JD, Dougall NJ, Best J, et al. Statistical parametric mapping of 99mTc HMPAO-SPECT images for the diagnosis of Alzheimer’s disease: normalizing to cerebellar tracer uptake. Neuroimage. 2002;17(3):1193-202.
8. Borghammer P, Østergaard K, Cumming P, Gjedde A, Rodell A, Hall N, et al. A deformation-based morphometry study of patients with early-stage Parkinson’s disease. Eur J Neurol. 2010;17(2):314-20.
9. Borghammer P. Perfusion and metabolism imaging studies in Parkinson’s disease. Eur J Neurol. 2012;17(2):314-20.
10. Adachi N, Watanabe T, Matsuda H, Onuma T. Hyperperfusion in the lateral temporal cortex the striatum and the thalamus during complex visual hallucination: single photon emission computed tomography findings in patients with Charles Bonnet syndrome. Psychiatry Clin Neurosci. 2000;54(2):157-62.
11. Borghammer P, Chakravarty M, Jonsdottir KY, Sato N, Matsuda H, Ito K, et al. Cortical hypometabolism and hypoperfusion in Parkinson’s disease is extensiveprobably even at early disease stages. Brain Struct Funct. 2010;214(4):303-17.
12. Scarmeas N, Habecka CG, Zarahna E, Anderson KE, Park A, Hilton J, et al. Covariance PET patterns in early Alzheimer’s disease and subjects with cognitive impairment but no dementia: utility in group discrimination and correlations with functional performance. Neuroimage. 2004;23(1):35-45.
13. Yakushev I, Hammers A, Fellgiebel A, Schmidtmann I, Scheurich A, Buchholz HG, et al. SPM-based count normalization provides excellent discrimination of mild Alzheimer’s disease and amnestic mild cognitive impairment from healthy aging. Neuroimage. 2009;44(1):43-50.
14. Borghammer P, Jonsdottir KY, Cumming P, Ostergaard K, Vang K, Ashkanian M, et al. Normalization in PET group comparison studies--the importance of a valid reference region. Neuroimage. 2008;40(2):529-40.
15. Andersson JL. How to estimate global activity independent of changes in local Activity. Neuroimage. 1997;6(4):237-44.
16. Buchsbaum MS, Buchsbaum BR, Hazlett EA, Haznedar MM, Newmark R, Tang CY, et al. Relative glucose metabolic rate higher in white matter in patients with schizophrenia. Am J Psychiatry. 2007;164(7):1072-81.
17. Videbech P, Ravnkilde B, Pedersen TH, Hartvig H, Egander A, Clemmensen K, et al. The Danish PET/ depression project: clinical symptoms and cerebral blood flow: a regions-of-interest analysis. Acta Psychiatr Scand. 2002;106(1):35-44.
18. Habeck C, Foster NL, Perneczky R, Kurz A, Alexopoulos P, Koeppe RA, et al. Multivariate and univariate neuroimaging biomarkers of Alzheimer’sdisease. Neuroimage. 2008;40(4):1503-15.
19. Borghammer P, Cumming P, Aanerud J, Gjedde A. Artefactual subcortical hyperperfusion in PET studies normalized to global mean: lessons from Parkinson’s disease. Neuroimage. 2009;45(2):249-57.
20. Borghammer P, Aanerud J, Gjedde A. Data-driven intensity normalization of PET group comparison studies is superior to global mean normalization. Neuroimage. 2009;46(4):981-8.
21. Maeda H, Yamaki N, Azuma M. Development of the software package of the nuclear medicine data processor for education and research. Nihon Hoshasen Gijutsu Gakkai Zasshi. 2012;68(3):299-306.
22. Worsley KJ, Liao CH, Aston J, Petre V, Duncan GH, Morales F, et al. A general statistical analysis for fMRI data. Neuroimage. 2002;15(1):1-15.
23. Worsley KJ, Marrett S, Neelin P, Vandal AC, Friston KJ, Evans AC. A unified statistical approach for determining significant signals in mages of cerebral activation. Hum Brain Map. 1996;4(1):58-73.